Table 1.
Analytical methods for the analysis of CPT-11 and metabolites in the literature
| Extraction | Analytes (Internal standard) | Assay | Matrix | LLOQa (ng/mL) | Reference |
|---|---|---|---|---|---|
| SPE | CPT-11, SN38 (Camptothecin) | HPLC-FLD | Human plasma | 1 | Barilero et al (1992) [17] |
| PPT | CPT-11, SN38 (Camptothecin) | HPLC-FLD | Human plasma | 10, 2 | Rivory et al (1994) [18] |
| LLE | CPT-11, SN38 (Camptothecin) | HPLC-FLD | Human plasma | 30, 1 | Sumiyoshi et al (1995) [19] |
| PPT | CPT-11, SN38 (Camptothecin) | HPLC-FLD | Human plasma | 2 | de Bruijn et al (1997) [20] |
| PPT | SN38 (none) | HPLC-FLD | Rat plasma | 5 | Kaneda et al (1997) [21] |
| PPT | CPT-11, SN38 (none) | HPLC-FLD | Rat and dog plasma | Chollet et al (1998) [22] | |
| PPT | CPT-11, SN38 SN38-G, APC (none) |
HPLC-FLD | Human plasma, urine, feces |
2, 100, 100 | Sparreboom et al (1998) [23] |
| LLE | SN38 (Camptothecin) | HPLC-FLD | Human plasma | 0.05 | de Bruijn et al (1999) [24] |
| SPE | CPT-11, SN38, SN38-G (Camptothecin) | HPLC-FLD | Rat plasma | 5, 5, 2.5 | Kurita et al (1999) [25] |
| PPT | CPT-11 (Camptothecin) | LC-MS | Human serum | 10 | Ragot et al (1999) [26] |
| LLE | SN38 (Camptothecin) | LC-MS | Human serum | 0.5 | Ragot et al (1999) [26] |
| PPT | CPT-11, SN38 (Camptothecin) | HPLC-FLD | Human plasma | 1, 0.5 | Escoriaza et al (2000) [27] |
| PPT | CPT-11, SN38, SN38-G | HPLC-FLD | Human plasma | 5, 1, 2.5 | Sai et al (2002) [28] |
| APC (none) | 2.5 | ||||
| PPT | CPT-11, SN38 (none) | HPLC-FLD | Human blood, RBCs | 5, 5 | de Jong et al (2003) [29] |
| LLE | SN38 (Camptothecin) | HPLC-FLD | Dog plasma | 1 | Guo et al (2003) [30] |
| PPT | SN38 (Camptothecin) | LC-MS/MS | Human plasma | 0.05 | Khan et al (2003) [31] |
| PPT | CPT-11, SN38, SN38-G | HPLC-FLD | Human plasma | 5, 0.5, 2 | Owens et al (2003) [32] |
| APC | 2 | ||||
| PPT | CPT-11, SN38 (Camptothecin) | LC-MS/MS | Mouse plasma, tissue | 0.5, 0.5 | Bardin et al (2005) [33] |
| PPT | SN38 (Camptothecin) | LC-MS/MS | Mouse plasma, tissue | 0.5, 1 | Khan et al (2005) [34] |
| SPE | CPT-11, SN38, APC (Camptothecin) | LC-MS/MS | Human plasma, liver microsomes | 1.5, 3.1, 0.78 | D’Esposito et al (2008) [35] |
| PPT | CPT-11, SN38 (Camptothecin) | LC-MS/MS | Human plasma | 10, 0.5 | Zhang et al (2009) [36] |
| PPT | CPT-11, SN38, SN38-G | LC-MS/MS | Human plasma | 0.5, 0.2, 0.5 | Corona et al (2010) [12] |
| APC, NPC (Camptothecin) | 0.5, 0.2 |
a
Abbreviations: LLOQ, lower limit of quantitation; PPT; SPE, solid phase extraction; HPLC-FLD, high performance liquid chromatography with fluorescence detection; LC-MS/MS, liquid chromatography with tandem mass spectrometric detection; SN38-G, glucuronide of SN38; APC, (7-ethyl-10-[4-N-(5-aminopentanoicacid)-1-piperidino]carbonyloxycamptothecin); NPC, (7-ethyl-10-[4-amino-1-piperidino]carbonyloxycamptothecin); RBCs, red blood cells;